38 research outputs found
Congenital Cytomegalovirus Infection
Infekcija citomegalovirusom (CMV) najuÄestalija je priroÄena virusna infekcija u ljudi i glavni je uzrok oÅ”teÄenja mozga u perinatalnom razdoblju. Zbog nastanka encefalitisa i razvojnih oÅ”teÄenja, kao posljedicu ima trajne neuroloÅ”ke poremeÄaje. Infekcija humanim citomegalovirusom (HCMV) kod veÄine osoba s normalnom funkcijom imunoloÅ”kog sustava ne izaziva kliniÄki manifesnu bolest. Zbog toga je infekcija HCMV-om u trudnoÄi Äesto neprepoznata, Å”to predstavlja dodatan rizik za razvoj kongenitalne infekcije HCMV-om. Uz to Å”to virus ima direktan citopatski uÄinak na neurone tijekom razvoja, samo prisustvo virusa u moždanom parenhimu dovodi do aktivacije upalnih stanica domaÄina i niza patohistoloÅ”kih lezija koje odgovaraju nastanku encefalitisa. Zbog toga bi daljnja istraživanja trebala biti usmjerena na razvoj sigurnog i uÄinkovitog cjepiva i lijekova koji Äe smanjiti rizik infekcije majki, a u sluÄaju prijelaza virusa s majke na dijete imati moguÄnost sprijeÄiti razvoj kongenitalne infekcije CMV-om.Cytomegalovirus (CMV) infection is the most common congenital viral infection in humans and the major cause of wide-spread encephalitis and developmental abnormalities of the newborn brain which can lead to several neurological consequences. Infection with the human CMV (HCMV) in patients with normal immune function does not cause a clinically manifest disease. As the HCMV infection in pregnancy is often unrecognized, it represents an additional risk for development of congenital HCMV infection. Beside the direct cytopathic effect of CMV on neurons during neurogenesis, the presence of the virus in brain parenchyme leads to the activation of host inflammatory response and development of pathohistological lesions. Therefore, further studies should be focused on development of safe and effective vaccines and drugs that will reduce the risk of maternal infection and in case of virus transfer from mother to child have the ability to prevent the development of congenital CMV infection
Congenital Cytomegalovirus Infection
Infekcija citomegalovirusom (CMV) najuÄestalija je priroÄena virusna infekcija u ljudi i glavni je uzrok oÅ”teÄenja mozga u perinatalnom razdoblju. Zbog nastanka encefalitisa i razvojnih oÅ”teÄenja, kao posljedicu ima trajne neuroloÅ”ke poremeÄaje. Infekcija humanim citomegalovirusom (HCMV) kod veÄine osoba s normalnom funkcijom imunoloÅ”kog sustava ne izaziva kliniÄki manifesnu bolest. Zbog toga je infekcija HCMV-om u trudnoÄi Äesto neprepoznata, Å”to predstavlja dodatan rizik za razvoj kongenitalne infekcije HCMV-om. Uz to Å”to virus ima direktan citopatski uÄinak na neurone tijekom razvoja, samo prisustvo virusa u moždanom parenhimu dovodi do aktivacije upalnih stanica domaÄina i niza patohistoloÅ”kih lezija koje odgovaraju nastanku encefalitisa. Zbog toga bi daljnja istraživanja trebala biti usmjerena na razvoj sigurnog i uÄinkovitog cjepiva i lijekova koji Äe smanjiti rizik infekcije majki, a u sluÄaju prijelaza virusa s majke na dijete imati moguÄnost sprijeÄiti razvoj kongenitalne infekcije CMV-om.Cytomegalovirus (CMV) infection is the most common congenital viral infection in humans and the major cause of wide-spread encephalitis and developmental abnormalities of the newborn brain which can lead to several neurological consequences. Infection with the human CMV (HCMV) in patients with normal immune function does not cause a clinically manifest disease. As the HCMV infection in pregnancy is often unrecognized, it represents an additional risk for development of congenital HCMV infection. Beside the direct cytopathic effect of CMV on neurons during neurogenesis, the presence of the virus in brain parenchyme leads to the activation of host inflammatory response and development of pathohistological lesions. Therefore, further studies should be focused on development of safe and effective vaccines and drugs that will reduce the risk of maternal infection and in case of virus transfer from mother to child have the ability to prevent the development of congenital CMV infection
Altered development of the brain after focal herpesvirus infection of the central nervous system
Human cytomegalovirus infection of the developing central nervous system (CNS) is a major cause of neurological damage in newborn infants and children. To investigate the pathogenesis of this human infection, we developed a mouse model of infection in the developing CNS. Intraperitoneal inoculation of newborn animals with murine cytomegalovirus resulted in virus replication in the liver followed by virus spread to the brain. Virus infection of the CNS was associated with the induction of inflammatory responses, including the induction of a large number of interferon-stimulated genes and histological evidence of focal encephalitis with recruitment of mononuclear cells to foci containing virus-infected cells. The morphogenesis of the cerebellum was delayed in infected animals. The defects in cerebellar development in infected animals were generalized and, although correlated temporally with virus replication and CNS inflammation, spatially unrelated to foci of virus-infected cells. Specific defects included decreased granular neuron proliferation and migration, expression of differentiation markers, and activation of neurotrophin receptors. These findings suggested that in the developing CNS, focal virus infection and induction of inflammatory responses in resident and infiltrating mononuclear cells resulted in delayed cerebellar morphogenesis
Diabetes mellitus and DPP IV/CD26 Inhibitors
Å eÄerna bolest ili dijabetes (lat. diabetes mellitus) metaboliÄka je bolest kroniÄne naravi, karakterizirana perzistentnom hiperglikemijom te poremeÄajima u metabolizmu ugljikohidrata, masti i proteina. Bolest se dijeli na dijabetes tipa 1 i 2, gestacijski dijabetes te ostale, manje zastupljene oblike. Zbog velikog rasta incidencije i prevalencije bolesti, rijeÄ je o znaÄajnom javno-zdravstvenom problemu te jednom od deset vodeÄih uzroka smrtnosti u svijetu. Dipeptidil-peptidaza IV, odnosno molekula CD26 (DPP IV/CD26, EC 3.4.14.5), ubikvitaran je multifunkcionalan transmembranski i solubilni glikoprotein te serinska peptidaza, prepoznat kao krucijalan Äimbenik u održavanju homeostaze glukoze u krvi, prije svega zbog moguÄnosti razgradnje inkretina. Znanstvena i kliniÄka ispitivanja ukazala su na visok terapijski potencijal inhibitora enzimske aktivnosti DPP IV/CD26 kod oboljelih od dijabetesa. Ovaj se pregledni rad fokusira na razliÄite aspekte dijabetesa tipa 1 i 2 te novije moguÄnosti terapije ovih oboljenja, s posebnim osvrtom na inhibitore DPP IV/CD26 kao efikasne terapijske opcije.Diabetes (lat. Diabetes mellitus) is a chronic metabolic disease characterized by persistent hyperglycaemia and carbohydrate, fat and protein metabolism disorders. Diabetes could be classified as type 1 or 2, gestational diabetes, and other, less common forms. Due to a prominent increase in the incidence and prevalence of the disease, it represents a significant public-health problem, being between the ten leading causes of mortality in the world. Dipeptidyl peptidase IV, or molecule CD26 (DPP IV / CD26, EC 3.4.14.5), is an ubiquitous multifunctional transmembrane and soluble glycoprotein and serine peptidase, recognized as a crucial factor in maintaining glucose homeostasis, primarily due to the ability to hydrolize incretins. Scientific and clinical studies have shown a high therapeutic potential of DPP IV/CD26 inhibitors in diabetic patients. This review focuses on various aspects of type 1 and 2 diabetes and newer treatment approaches for these diseases, with a special focus on DPP IV/CD26 inhibitors as effective therapeutic options
Wound healing process and dipeptidyl peptidase IV
Cijeljenje rane dinamiÄan je proces koji se odvija u viÅ”e meÄuovisnih faza koje ukljuÄuju reguliranu interakciju meÄu razliÄitim vrstama stanica, izvanstaniÄnog matriksa, proteaza i njihovih supstrata. RastuÄi znanstveni dokazi naglaÅ”avaju važnost proteaza u regulaciji kljuÄnih procesa cijeljenja rane. Dipeptidil-peptidaza IV (DPP IV/CD26, EC 3.4.14.5), glavni je Älan obitelji DPP IV proteina. RijeÄ je o ubikvitarnom multifunkcionalnom transmembranskom glikoproteinu koji je prisutan i u topljivom obliku, a djeluje kao proteolitiÄka i kostimulacijska molekula te vezni protein. Izražena je na povrÅ”ini razliÄitih vrsta stanica, ukljuÄujuÄi epitelne, endotelne stanice i limfocite. Pokazano je da ima znaÄajnu ulogu u razliÄitim fizioloÅ”kim i patoloÅ”kim procesima. DPP IV/CD26 je u velikoj mjeri istraživana zbog svoje sposobnosti održavanja homeostaze glukoze. Å toviÅ”e, buduÄi na utvrÄene pozitivne uÄinke inhibicije DPP IV/CD26 u cijeljenju kroniÄnih dijabetiÄkih ulkusa, kao i ukljuÄenosti u drugim patoloÅ”kim procesima, ova je molekula od rastuÄeg znanstvenog interesa u cilju razjaÅ”njavanja mehanizama njezinog djelovanja. Poznato je da DPP IV/CD26 sudjeluje u regulaciji staniÄne adhezije, migracije i apoptoze stanica kao i angiogenezi te razgradnji ekstracelularnog matriksa, kljuÄnim procesima u cijeljenju rana. Prethodne studije pokazale su da DPP IV/CD26 ima posebno važnu ulogu u regeneraciji kože, gdje je utvrÄeno da može posredovati upalne procese i utjecati na epitelizaciju ranjenog tkiva. Stoga je cilj ovog preglednog rada sažeti kljuÄna otkriÄa u procesima cijeljenja rana te prikazati nove spoznaje o ulozi DPP IV/CD26 u procesima regeneracije tkiva.Wound healing is a dynamic process occurring in multiple interdependent stages that include a regulated interaction between different cell types, extracellular matrix, proteases and their substrates. Increasing scientific evidence emphasizes the importance of proteases playing crucial roles in the regulation of processes of wound healing. Dipeptidyl peptidase IV (DPP IV/CD26, EC 3.4.14.5), the main member of the DPP IV family of proteins, is a ubiquitous multifunctional transmembrane as well as soluble glycoprotein, acting as a proteolytic and costimulation molecule, and binding protein. It is expressed on the surface different cell types, including epithelial, endothelial cells and lymphocytes. It has been shown to play a significant role in different physiological as well as pathological processes. DPP IV/ CD26 was largely investigated given its ability to maintain glucose homeostasis. Moreover, since positive effects of DPP IV/CD26 inhibition in healing of chronic diabetic foot ulcers as well as other pathologies have been shown, growing efforts are made in order to elucidate its mechanisms of action. It is known that DPP IV/CD26 is involved in the regulation of cell adhesion, migration, apoptosis, angiogenesis and extracellular matrix degradation, which are all key processes in wound healing. Previous studies indicated that DPP IV/CD26 plays a particularly relevant role in skin regeneration where it was found to mediate inflammatory processes and influence epithelialization of wounds. Therefore, the aim of this review was to summarize crucial findings regarding wound healing as well as new insights about the involvement of DPP IV/CD26 in tissue regeneration
Relevance of DPP IV/CD26 among the Gut-brain Axis during Experimental Colitis
Inflammatory bowel diseases (IBD) represent a group of chronic conditions of the gastrointestinal
tract of unknown etiology. Latest knowledge accentuates the bidirectional connection between the central and
enteric nervous systems. An important role of peptidases has been proposed in maintaining the homeostasis
in the gut. One of them is dipeptidil-peptidase IV (DPP IV/CD26), a multifunctional glycoprotein found in
both soluble and membrane-bound form in living organisms. In order to evaluate the relevance of DPP
IV/CD26 among the gut-brain axis, a TNBS (Crohn-like) model of colitis has been induced in CD26 deficient
and wild type mice. Results of this study showed that CD26 deficient mice show specificity in histological
damage compared to wild type mice. A decreased DPP IV/CD26 activity was found in serum, colon and
brain in wild type mice with colitis, while CD26 protein expression was increased in colon of those mice.
DPP IV/CD26-like activity was decreased only in colon of CD26 deficient mice. Changes occurring during
inflammatory processes in colon reflected on investigated parameters in brain. Therefore, our results indicate
the importance of the gut-brain axis in the pathogenesis of IBD. (doi: 10.5562/cca1813
Diabetes, Dipeptidyl Peptidase iv and Wound Healing: from Basic Science to Therapeutic Possibilities
Hyperglycemia, often accompanied with various complications such as chronic ulcers, represents a major socio-economic health problem. Dipeptidyl peptidase IV or CD26 molecule (DPP IV/CD26), is an omnipresent transmembrane protein with significant involvements in different physiological and pathological processes. It has been recognized as a therapeutic option in the treatment of hyperglycemia, especially in patients suffering from type 2 diabetes, given its capability to regulate the biological activity of incretins, which are major regulators of glucose homeostasis. Furthermore, DPP IV/CD26 has been indicated to be involved in the regulation of inflammatory processes as well as cell proliferation and angiogenesis. New scientific evidence shows that inhibition of DPP IV/CD26 leads to a more efficacious healing of chronic ulcers in diabetic patients as well as in mice models of wounded tissue restoration. However, the role of DPP IV/CD26 in the process of wound healing in hyperglycemia is not entirely known. Our aim was to summarize most important findings on the involvement of DPP IV/CD26 in the regulation of glycemia as well as tissue regeneration and reparation. This work reviews basic biochemical
Wound Healing Process, Diabetes and Implications of Dipeptidyl Peptidase IV (DPP IV/CD26
Dipeptidyl Peptidase IV or molecule CD26 (DPP IV/CD26) is a multifunctional protein, identified as a therapeutic
target for type 2 diabetes, due to its ability to degrade incretins, insulin secretagogues. Delayed wound healing is
a significant complication in diabetic patients that represents a major socio-economic health problem. It has been
proposed that DPP IV/CD26 inhibition accelerates healing of chronic diabetic ulcers in those patients, through the
induction of a histological pattern consistent with enhanced angiogenesis. Studies on mice models of diabetesdisturbed
wound healing also suggested that the inhibition of DPP IV enzymatic activity may improve tissue
regeneration processes. However, further research is needed to elucidate the role of DPP IV/CD26 in diabetic
wound healing. The objective of this work was to discuss recent findings on the implications of DPP IV/CD26 in tissue
regeneration and reparation in diabetic environmen
Clinical Relevance of CD-68 Positive Cells in Normal Buccal Mucosa in Patients with Inflammatory Bowel Disease
The aim of this study was to investigate the presence of microaggregates of macrophages (CD-
68 positive cells) in macroscopically normal buccal mucosa in patients with inflammatory bowel disease
(IBD). Fifty two patients with clinically and pathohistologically diagnosed IBD, thirty patients with
Crohnās disease (CD), twenty two patients with ulcerative colitis (UC), and twenty five controls, matched
for sex and age, were involved. The occurrence of CD-68 positive cells microaggregates was more frequent
in CD patients comparing with UC patients (P = 0.0093), and the controls (P = 0.0001) respectively.
There was no statistically significant difference in occurrence of CD-68 positive microaggregates in
patients with positive microbiological findings (P = 0.8258). The results suggest that microaggregates of
macrophages are more frequently present in apparently normal buccal mucosa in patients with CD than in
patients with UC independently of microbiological findings. Therefore, it could be a potential marker for
differentiating patients with Crohnās disease from UC patients, when standard tools failed. (doi:
10.5562/cca1779